









Markets
/
Stocks
/
nasdaq-sldb
/

Solid Biosciences Inc

SLDB

7.110USD

-0.620-8.02%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

551.76MMarket Cap

LossP/E TTM



Solid Biosciences Inc

7.110

-0.620-8.02%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Solid Biosciences Inc

Currency: USD Updated: 2026-03-27

Key Insights

Solid Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 38 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Solid Biosciences Inc's Score

Industry at a Glance

Industry Ranking

38 / 391

Overall Ranking

135 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Solid Biosciences Inc Highlights

StrengthsRisks

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -3.57, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 82.70M shares, decreasing 17.41% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 6.48K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.46.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

17.500

Target Price

+126.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Solid Biosciences Inc is 6.75, ranking 209 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.75

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.75

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Solid Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Solid Biosciences Inc is 6.64, ranking 239 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.57, which is -101.48% below the recent high of 0.05 and -8.72% above the recent low of -3.88.

Score

Industry at a Glance

Previous score

6.64

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Solid Biosciences Inc is 8.86, ranking 43 out of 391 in the Biotechnology & Medical Research industry. The average price target is 15.00, with a high of 20.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

17.500

Target Price

+126.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Solid Biosciences Inc

SLDB

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Solid Biosciences Inc is 7.58, ranking 38 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.71 and the support level at 5.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.30

Change

-1.72

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.075

Neutral

RSI(14)

51.805

Neutral

STOCH(KDJ)(9,3,3)

45.690

Neutral

ATR(14)

0.718

Low Volatility

CCI(14)

-11.030

Neutral

Williams %R

75.943

Sell

TRIX(12,20)

0.604

Sell

StochRSI(14)

34.349

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.178

Sell

MA10

7.240

Sell

MA20

7.100

Buy

MA50

6.591

Buy

MA100

5.904

Buy

MA200

5.803

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Solid Biosciences Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 106.15%, representing a quarter-over-quarter increase of 0.54%. The largest institutional shareholder is The Vanguard, holding a total of 3.45M shares, representing 3.51% of shares outstanding, with 10.63% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

11.83M

-0.61%

RA Capital Management, LP

5.81M

Invus Public Equities Advisors, LLC

7.42M

Vestal Point Capital, LP

2.98M

+97.67%

Bain Capital Life Sciences Investors, LLC

7.91M

BlackRock Institutional Trust Company, N.A.

4.06M

-7.08%

The Vanguard Group, Inc.

Star Investors

3.08M

-8.37%

Citadel Advisors LLC

2.59M

+2.75%

Armistice Capital LLC

936.00K

+134.00%

Point72 Asset Management, L.P.

Star Investors

1.33M

+5.29%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Solid Biosciences Inc is 3.70, ranking 122 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 2.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.